ClinicalTrials.gg
RecruitingNCT07145697Updated Oct 27, 2026

The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness

A Phase 4 interventional study of Dexmedetomidine in Consciousness, Level Altered, sponsored by Guangzhou General Hospital of Guangzhou Military Command. Recruiting at 1 site in China. Open to participants aged 3 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Guangzhou General Hospital of Guangzhou Military Command · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 27, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
3 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Consciousness Disorders with a site in China — 30 open to participants now, 31 under way, 1 of them phase 3. Consciousness Disorders · China.

Planned enrollment
32nd of 40
30 · median 60
Started
2025
with 6 others
Phase 4
2 of 70
1 open now
Primary completion
2027-12
later than 26 of 30 live
Registered
58th of 70
by date

Among the 70 studies in Consciousness Disorders with a site in China, this one is the 32nd largest by planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 26 of the 30 other live ones, and was the 58th registered.

Consciousness Disorders

291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.

Browse Consciousness Disorders studies →

Open to participants now

30 of the 70 studies in Consciousness Disorders with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.

This study: 3 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Consciousness Disorders with a site in China, or all of them as a file.
02

Study summary

In the field of general anesthesia research, the neural mechanism underlying the loss of consciousness has long been a highly core issue. It remains unclear what consciousness is and how it emerges from brain activity. By studying anesthesia and sleep, the investigators aim to reveal what happens in the brain when consciousness is lost and when it returns.

Dexmedetomidine, a widely used drug in clinical anesthetic practice, plays an important role in the anesthetic process due to its unique pharmacological properties. It hardly causes respiratory depression during the sedative and hypnotic process, which makes it occupy an important position in clinical anesthetic regimens.

The emergence of stereoelectroencephalography (SEEG) technology has brought new opportunities for research on anesthesia mechanisms. Compared with traditional electroencephalographic (EEG), SEEG can directly penetrate into deep brain structures to record electrical activities, enabling precise localization of brain regions closely related to consciousness regulation.

At present, although there have been some studies on the effects of dexmedetomidine on EEG activities, there are still many deficiencies. Most studies have focused on simple spectral analysis of EEG signals or observations of limited brain regions, lacking comprehensive multi-dimensional research on functional connectivity between brain regions, microstates, and complexity. Through monitoring key brain regions, the SEEG technology can obtain more targeted and accurate information, thereby providing strong support for comprehensively revealing the neural mechanisms of dexmedetomidine-induced loss of consciousness.

03

Conditions studied

  • Consciousness, Level Altered
04

Who can participate

Ages eligible
3 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range: 1 - 65 years old
  2. : 18.5 - 25.0 kg/m²
  3. classification: I - III
  4. Patients diagnosed with drug - epilepsy who, after long - term monitoring of epileptic seizures, require stereo-electroencephalography (SEEG) electrode implantation based on the clinical need for monitoring their epilepsy.
  5. Patients voluntarily participate in this study and sign a written form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe arrhythmia or other organic heart diseases;
  2. Patients with comorbid obstructive sleep apnea-hypopnea syndrome (OSAHS);
  3. Patients with hepatic or renal dysfunction; those with a history of immunodeficiency diseases , or a history of cancer/malignant tumors, or a history of diseases, or severe cardiovascular and cerebrovascular diseases, or other diseases that may significantly reduce ;
  4. Patients with any history of diseases that may affect protocol compliance (such as severe mental disorders, disturbance of consciousness; cognitive dysfunction, drug abuse or addiction, etc.);
  5. Pregnant or lactating women, or those of who are unwilling/unable to take effective measures;
  6. Patients with known allergies to the ingredients contained in the drugs used in this study;
  7. Patients who have participated in any drug clinical trial within 6 months before the screening examination;
  8. Patients who are deemed unsuitable to participate in this study by the researcher.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • No intervention
    Sleep

    Recordering electroencephalograms during nighttime natural sleep.

  • Experimental
    Dexmedetomidine

    Escalating concentrations until loss of responsiveness

    Drug: Dexmedetomidine

Interventions

06

What researchers measure

Primary outcomes

  1. Stereo-electroencephalography

    Time frame: After the patient has completed the monitoring of epileptic seizures due to clinical needs, they can participate in this test. Through test completion, an average of 3 hours.

Secondary outcomes

  1. Functional connectivity

    permutation mutual information (PMI); stereo-electroencephalography assessment parameter

    Time frame: through test completion, an average of 3 hours

  2. The complexity

    examined by permutation entropy (PE); stereo-electroencephalography assessment parameter

    Time frame: through test completion, an average of 3 hours

  3. Phase-amplitude coupling (PAC)

    PAC is used to illuminate cross-frequency coordination in neurophysiological activity of electroencephalogram. stereo-electroencephalography assessment parameter

    Time frame: through test completion, an average of3 hours.

  4. Directional connectivity

    symbolic conditional mutual information (SCMI) and directionality index (DI); stereo-electroencephalography assessment parameter

    Time frame: through test completion, an average of 3 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Apr 2025 → Sep 2025, primary completion Dec 2026 → Dec 2027 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 28, 2025
StartActual
Sep 1, 2025was Apr 2025
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Jun 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 10, 2025→Sep 1, 2025
Oct 27, 2026
Primary completion
Dec 31, 2026→Dec 31, 2027
Oct 27, 2026
Study completion
Jun 30, 2027→Dec 31, 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Apr 10, 2025→Sep 1, 2025
    Primary completion Dec 31, 2026→Dec 31, 2027
    Study completion Jun 30, 2027→Dec 31, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07145697
Lead sponsor
Guangzhou General Hospital of Guangzhou Military Command
Responsible party
bo xu (Clinical Professor, Guangzhou General Hospital of Guangzhou Military Command) — Principal investigator
First posted
Aug 28, 2025
Start date
Sep 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion